• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency.

April 8, 2013 | Proceedings of the National Academy of Sciences of the United States of America
Kannan Tharakaraman et al.

Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency.

Kannan Tharakaraman, Luke N Robinson, Andrew Hatas, Yi-Ling Chen, Liu Siyue, S Raguram, V Sasisekharan, Gerald N Wogan, Ram Sasisekharan

>READ

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design